Glycopyrrolate/rivastigmine

Drug Profile

Glycopyrrolate/rivastigmine

Alternative Names: RVT 104

Latest Information Update: 19 Oct 2016

Price : $50

At a glance

  • Originator Axovant Sciences
  • Class Antidementias; Phenylcarbamates; Pyrrolidines; Small molecules
  • Mechanism of Action Acetylcholinesterase inhibitors; Butyrylcholinesterase inhibitors; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Alzheimer's disease; Lewy body disease

Most Recent Events

  • 13 Jun 2017 Axovant Sciences plans a phase I proof of concept study for Alzheimers disease and Lewy body disease in the second half of 2017
  • 15 Aug 2016 Early research in Alzheimer's disease in Bermuda (unspecified route) after August 2016
  • 15 Aug 2016 Early research in Lewy body disease in Bermuda (unspecified route) after August 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top